Format

Send to

Choose Destination
Haematologica. 2016 Feb;101(2):e66-8. doi: 10.3324/haematol.2015.132811. Epub 2015 Oct 15.

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

Author information

1
Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Italy sluminari@unimore.it.
2
Department of Internal and Experimental Medicine, University of Pisa, UO Hematology, Italy.
3
Department of Nuclear Medicine, Arcispedale S. Maria Nuova - IRCCS of Reggio Emilia, Italy.
4
Department of Medicine, University Hospital and School of Medicine, Universidade Federal do Rio de Janeiro, Brazil.
5
Hematology Unit, Spedali Civili di Brescia, Italy.
6
Division of Hematology, Department of Hematology and Oncology, Niguarda Hospital, Milan, Italy.
7
Hematology Unit, Arcispedale Santa Maria Nuova, IRCCS of Reggio Emilia, Italy.
8
Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Italy.

KEYWORDS:

FDG-PET; follicular lymphoma; minimal residual disease; nuclear medicine; progression-free survival

PMID:
26471485
PMCID:
PMC4938338
DOI:
10.3324/haematol.2015.132811
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center